PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2022-05-06. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. The company is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Follow-Up Questions
PepGen Inc 'in CEO'su kimdir?
Dr. James Mcarthur 2021 'den beri şirketle birlikte olan PepGen Inc 'in President 'ıdır.
PEPG hissesinin fiyat performansı nasıl?
PEPG 'in mevcut fiyatı $2.28 'dir, son işlem günde 11.46% increased etti.
PepGen Inc için ana iş temaları veya sektörler nelerdir?
PepGen Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
PepGen Inc 'in piyasa değerlemesi nedir?
PepGen Inc 'in mevcut piyasa değerlemesi $74.9M 'dir
PepGen Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 8 analist PepGen Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 5 güçlü al, 4 al, 1 tut, 1 sat ve 5 güçlü sat içermektedir
